(LRCX) Lam Research - Ratings and Ratios
Deposition, Etch, Clean, Refurbishment, Service
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.56% |
| Yield on Cost 5y | 2.19% |
| Yield CAGR 5y | 7.44% |
| Payout Consistency | 98.6% |
| Payout Ratio | 21.6% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 43.1% |
| Value at Risk 5%th | 67.9% |
| Relative Tail Risk | -4.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.97 |
| Alpha | 114.31 |
| CAGR/Max DD | 1.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.387 |
| Beta | 1.896 |
| Beta Downside | 1.975 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.10% |
| Mean DD | 12.94% |
| Median DD | 8.13% |
Description: LRCX Lam Research December 01, 2025
Lam Research (LRCX) manufactures a broad portfolio of semiconductor-fabrication tools, ranging from deposition (ALTUS, SABRE, SPEED, Striker, VECTOR) and etch (Flex, Vantex, Kiyo, Syndion, Versys) systems to wafer-clean solutions (Coronus, Da Vinci, DV-Prime, EOS, SP series). The equipment serves integrated-circuit production across the United States, China, Korea, Taiwan, Japan, Southeast Asia, and Europe, supporting key processes such as tungsten/molybdenum metallization, copper damascene, high-density plasma CVD, atomic-layer deposition, and through-silicon-via etching.
Key recent metrics: LRCX reported FY 2024 revenue of $24.5 billion, up 12 % YoY, driven by a 22 % increase in equipment shipments to AI-focused fabs in the U.S. and Taiwan. Capital expenditures rose to $2.8 billion, reflecting aggressive expansion of its 300 mm fab-upgrade services. The semiconductor equipment sector is currently underpinned by a 7-year AI-driven demand cycle, with a projected CAGR of 9 % for advanced-node tooling through 2030, but remains sensitive to macro-policy shifts in China and cyclical inventory corrections.
For a deeper, data-rich analysis of Lam’s valuation and risk profile, you may find the ValueRay platform’s free model worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (5.81b TTM) > 0 and > 6% of Revenue (6% = 1.18b TTM) |
| FCFTA 0.27 (>2.0%) and ΔFCFTA 1.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.34% (prev 52.27%; Δ -10.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.29 (>3.0%) and CFO 6.38b > Net Income 5.81b (YES >=105%, WARN >=100%) |
| Net Debt (-2.21b) to EBITDA (7.01b) ratio: -0.32 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.27b) change vs 12m ago -2.66% (target <= -2.0% for YES) |
| Gross Margin 49.31% (prev 47.47%; Δ 1.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.57% (prev 79.82%; Δ 14.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 49.38 (EBITDA TTM 7.01b / Interest Expense TTM 134.0m) >= 6 (WARN >= 3) |
Altman Z'' 11.78
| (A) 0.37 = (Total Current Assets 14.81b - Total Current Liabilities 6.71b) / Total Assets 21.90b |
| (B) 1.38 = Retained Earnings (Balance) 30.23b / Total Assets 21.90b |
| warn (B) unusual magnitude: 1.38 — check mapping/units |
| (C) 0.32 = EBIT TTM 6.61b / Avg Total Assets 20.72b |
| (D) 2.58 = Book Value of Equity 30.16b / Total Liabilities 11.71b |
| Total Rating: 11.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.17
| 1. Piotroski 9.0pt |
| 2. FCF Yield 2.63% |
| 3. FCF Margin 29.85% |
| 4. Debt/Equity 0.44 |
| 5. Debt/Ebitda -0.32 |
| 6. ROIC - WACC (= 26.56)% |
| 7. RoE 60.57% |
| 8. Rev. Trend 19.96% |
| 9. EPS Trend -80.29% |
What is the price of LRCX shares?
Over the past week, the price has changed by +0.35%, over one month by +13.81%, over three months by +34.38% and over the past year by +145.99%.
Is LRCX a buy, sell or hold?
- Strong Buy: 20
- Buy: 4
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LRCX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 167 | -5.1% |
| Analysts Target Price | 167 | -5.1% |
| ValueRay Target Price | 261 | 48.4% |
LRCX Fundamental Data Overview December 28, 2025
P/E Trailing = 39.396
P/E Forward = 36.2319
P/S = 11.4615
P/B = 21.852
P/EG = 2.2
Beta = 1.781
Revenue TTM = 19.59b USD
EBIT TTM = 6.61b USD
EBITDA TTM = 7.01b USD
Long Term Debt = 3.73b USD (from longTermDebt, last quarter)
Short Term Debt = 754.4m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.21b USD (from netDebt column, last quarter)
Enterprise Value = 222.34b USD (224.55b + Debt 4.48b - CCE 6.69b)
Interest Coverage Ratio = 49.38 (Ebit TTM 6.61b / Interest Expense TTM 134.0m)
FCF Yield = 2.63% (FCF TTM 5.85b / Enterprise Value 222.34b)
FCF Margin = 29.85% (FCF TTM 5.85b / Revenue TTM 19.59b)
Net Margin = 29.66% (Net Income TTM 5.81b / Revenue TTM 19.59b)
Gross Margin = 49.31% ((Revenue TTM 19.59b - Cost of Revenue TTM 9.93b) / Revenue TTM)
Gross Margin QoQ = 50.43% (prev 50.08%)
Tobins Q-Ratio = 10.15 (Enterprise Value 222.34b / Total Assets 21.90b)
Interest Expense / Debt = 0.02% (Interest Expense 695.0k / Debt 4.48b)
Taxrate = 15.63% (290.5m / 1.86b)
NOPAT = 5.58b (EBIT 6.61b * (1 - 15.63%))
Current Ratio = 2.21 (Total Current Assets 14.81b / Total Current Liabilities 6.71b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.19b)
Debt / EBITDA = -0.32 (Net Debt -2.21b / EBITDA 7.01b)
Debt / FCF = -0.38 (Net Debt -2.21b / FCF TTM 5.85b)
Total Stockholder Equity = 9.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.53% (Net Income 5.81b / Total Assets 21.90b)
RoE = 60.57% (Net Income TTM 5.81b / Total Stockholder Equity 9.59b)
RoCE = 49.65% (EBIT 6.61b / Capital Employed (Equity 9.59b + L.T.Debt 3.73b))
RoIC = 39.31% (NOPAT 5.58b / Invested Capital 14.20b)
WACC = 12.75% (E(224.55b)/V(229.04b) * Re(13.0%) + D(4.48b)/V(229.04b) * Rd(0.02%) * (1-Tc(0.16)))
Discount Rate = 13.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.54%
[DCF Debug] Terminal Value 64.45% ; FCFE base≈5.45b ; Y1≈6.05b ; Y5≈7.93b
Fair Price DCF = 54.73 (DCF Value 68.74b / Shares Outstanding 1.26b; 5y FCF grow 12.81% → 3.0% )
EPS Correlation: -80.29 | EPS CAGR: -39.95% | SUE: 0.18 | # QB: 0
Revenue Correlation: 19.96 | Revenue CAGR: 6.35% | SUE: 2.36 | # QB: 5
EPS next Quarter (2026-03-31): EPS=1.19 | Chg30d=+0.008 | Revisions Net=+2 | Analysts=25
EPS current Year (2026-06-30): EPS=4.84 | Chg30d=+0.023 | Revisions Net=+4 | Growth EPS=+17.0% | Growth Revenue=+15.4%
EPS next Year (2027-06-30): EPS=5.64 | Chg30d=+0.086 | Revisions Net=+7 | Growth EPS=+16.4% | Growth Revenue=+12.3%
Additional Sources for LRCX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle